These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 27807662

  • 1. C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells.
    Jiang S, Wang Q, Feng M, Li J, Guan Z, An D, Dong M, Peng Y, Kuerban K, Ye L.
    Appl Microbiol Biotechnol; 2017 Feb; 101(4):1535-1546. PubMed ID: 27807662
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J, Zhai B, Sun W, Hu F, Cheng H, Xu J.
    PLoS One; 2017 Feb; 12(9):e0185088. PubMed ID: 28934275
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.
    Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
    [Abstract] [Full Text] [Related]

  • 8. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
    Yokoi K, Kobayashi A, Motoyama H, Kitazawa M, Shimizu A, Notake T, Yokoyama T, Matsumura T, Takeoka M, Miyagawa SI.
    Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
    Tan W, Zhu S, Cao J, Zhang L, Li W, Liu K, Zhong J, Shang C, Chen Y.
    Oncol Res; 2017 Nov 02; 25(9):1543-1553. PubMed ID: 28276313
    [Abstract] [Full Text] [Related]

  • 10. SKI-349, a Sphingosine Kinases 1/2 Inhibitor, Suppresses Cell Viability, Invasion, and AKT/mTOR Signaling Pathway, and Shows Synergistic Cytotoxic Effects with Sorafenib in Hepatocellular Carcinoma.
    Chen L, Wang L, Han Z, Qin P, Niu G, Du J.
    Tohoku J Exp Med; 2024 Mar 15; 262(3):173-180. PubMed ID: 38123304
    [Abstract] [Full Text] [Related]

  • 11. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M, Fei Z, Zhang G.
    Biomed Pharmacother; 2018 Jan 15; 97():1282-1288. PubMed ID: 29156516
    [Abstract] [Full Text] [Related]

  • 12. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Pal HC, Baxter RD, Hunt KM, Agarwal J, Elmets CA, Athar M, Afaq F.
    Oncotarget; 2015 Sep 29; 6(29):28296-311. PubMed ID: 26299806
    [Abstract] [Full Text] [Related]

  • 13. Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT, and PI3K expression.
    Zhang CZ, Wang XD, Wang HW, Cai Y, Chao LQ.
    J BUON; 2015 Sep 29; 20(1):218-22. PubMed ID: 25778319
    [Abstract] [Full Text] [Related]

  • 14. Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/Stat3, ERK/MAPK, PI3K/Akt/mTOR signaling pathways.
    Üremiş MM, Üremiş N, Türköz Y.
    Steroids; 2023 Oct 29; 198():109261. PubMed ID: 37355001
    [Abstract] [Full Text] [Related]

  • 15. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH, Tian HY, Fung KP, Kurihara H, Pan JX, Ye WC.
    Carcinogenesis; 2013 Jun 29; 34(6):1331-42. PubMed ID: 23393227
    [Abstract] [Full Text] [Related]

  • 16. The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma.
    Yu CC, Huang SY, Chang SF, Liao KF, Chiu SC.
    Molecules; 2020 May 25; 25(10):. PubMed ID: 32466169
    [Abstract] [Full Text] [Related]

  • 17. NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.
    Yu P, Ye L, Wang H, Du G, Zhang J, Zhang J, Tian J.
    Tumour Biol; 2015 Mar 25; 36(3):2143-53. PubMed ID: 25398692
    [Abstract] [Full Text] [Related]

  • 18. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
    Gedaly R, Galuppo R, Musgrave Y, Angulo P, Hundley J, Shah M, Daily MF, Chen C, Cohen DA, Spear BT, Evers BM.
    J Surg Res; 2013 Nov 25; 185(1):225-30. PubMed ID: 23769634
    [Abstract] [Full Text] [Related]

  • 19. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
    Dai N, Ye R, He Q, Guo P, Chen H, Zhang Q.
    Oncol Rep; 2018 Dec 25; 40(6):3235-3248. PubMed ID: 30272354
    [Abstract] [Full Text] [Related]

  • 20. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
    Mao J, Yang H, Cui T, Pan P, Kabir N, Chen D, Ma J, Chen X, Chen Y, Yang Y.
    Eur J Pharmacol; 2018 Aug 05; 832():39-49. PubMed ID: 29782854
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.